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Abstract: Barrett's esophagus (BE) is a displacement of the squamocolumnar border (SCJ) site to proximal to the 
gastroesophageal junction (GEJ) accompanied by the presence of intestinal metaplasia. BE develops when 
reflux-induced stomach acid destroys the squamous epithelial layer of the esophagus and this lesion heals 
via a metaplasia process in which the damaged squamous epithelial layer is replaced by columnar colon-
type epithelium. BE prevalence in the general population is about 1.6-1.7%. Patients with gastroesophageal 
reflux disease (GERD) may progress to BE. This report concerns two cases of patients with Barrett's 
esophagus. In both these patients BE was found without dysplasia. A diagnosis was made on the basis of 
anamnesis, physical examination, laboratory, radiological, endoscopy and anatomical pathology. The 
management of BE is aimed at three main objectives: reduction of symptoms due to GERD, avoiding 
progression to strictures and ulcers, and preventing progression to adenocarcinoma. Both patients were 
given a PPI, a prokinetic and chemoprevention NSAID which achieved clinical improvement. Neither 
patient had ablation, photodynamic or mucosal resection. BE survival is much better than in groups without 
BE (5 years survival 61% vs. 28%, P = 0.001). 
 
1 INTRODUCTION 
The name Barrett's esophagus (BE) was coined 
when a London surgeon, R. Barrett N, described it in 
the 1950s. This definition continues to evolve, which 
initially included all of the three types of columnar 
epithelium, namely the fundal mucosa, cardia and 
intestinal metaplasia. However, there is currently a 
general consensus, namely the use of intestinal 
metaplasia and not using the other two types of 
mucosa, as markers for BE histology. The definition 
of BE according to the American 
Gastroenterological Association is the displacement 
of the squamocolumnar border (SCJ) site to 
proximal to the gastroesophageal junction (GEJ) 
accompanied by the presence of intestinal 
metaplasia (Bansal, 2007; Pascu, 2004).   
BE prevalence in the general population is about 
1.6-1.7%. Approximately 10-15% of patients with 
Gastroesophageal reflux disease (GERD) develop 
BE, where the incidence of BE developing into 
adenocarcinoma is 0.5% per year. Compared to 
normal people, the risk of esophageal cancer is 30-
50 times, with an average age of 55-65 years. More 
than 80% are white with a 2:1 male to female ratio 
(Zanten et al., 2006; Wang, 2008; Poneros, 2009).  
BE diagnosis is based on existing symptoms and 
risk factors, as well as the discovery of endoscopic 
layers of the columnar epithelium at the distal 
esophagus and is determined by the presence of 
intestinal metaplasia in biopsy specimens. BE is 
categorized based on how long the metaplasia layer 
limit is measured by endoscopy examination. It is 
called a long segment if its length is 3 cm or more, 
whereas if it is less than this it is called a short 
segment. If no columnar esophageal mucosa is 
found but intestinal metaplasia is via biopsy under 
the GEJ then it is called cardia intestinal metaplasia 
(CIM) (Bansal, 2007; Poneros, 2009; Spechler, 
2002a). 
BE develops when reflux-induced stomach acid 
destroys the squamous epithelial layer of the 
esophagus and this lesion heals via a metaplasia 
process in which the damaged squamous epithelial 
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layer is replaced by columnar colon-type epithelium. 
Studies have shown the presence of incompetent 
mechanics in the lower esophageal sphincter, low 
clearance, frequency and duration of reflux episodes, 
and peristaltic wave amplitude in both BE types is 
significantly lower than in normal people (Zentilin et 
al., 2002; Lord, 2003).  
2 CASE PRESENTATION 
2.1 Case 1    
We report a male patient, Mr. H, aged 30, 
unmarried, Chinese, bachelor’s degree, working in a 
private company (marketing), living in Surabaya, 
who came for medication with a major complaint of 
heartburn in the chest.  
The patient complained of heartburn in the chest 
for 14 years. It frequently recurs, and sometimes the 
burning sensation is up to the larynx. The complaints 
worsen if he lies flat, consumes fatty foods or coffee. 
In addition, the patient complained of nausea, 
vomiting, bloating and heartburn. There was also 
constipation that disappeared causing him to often 
consume traditional medicine. There was no 
swallowing pain or swallowing difficulty, black 
feces and black vomiting like coffee, weight loss, or 
fatigue. 
He first had recurring shortness of breath for 7 
years before and was diagnosed with bronchitis. He 
had a history of maxillary sinusitis for 7 years. There 
was a history of a diet low in vegetables and fruit 
and a history of treatment with ranitidine and 
antacids. There were no smoking history, history of 
drinking alcohol, history of frequent drinking of 
coffee, history of traditional medicine (ching sung), 
high blood pressure and diabetes.  
Based on a physical examination, it was found 
that his general condition was moderate, good 
awareness and was compos mentis. Blood pressure 
(BP) 120/80 mmHg, pulse 84 x / min, axillary 
temperature 36.7°C, respiration 20 x / min and body 
weight 89 kg, Height of 173 cm and BMI 29.73. On 
examination of the head and neck no anemia, 
jaundice, cyanosis, dyspnea or enlarged lymph 
nodes (ELN) were found. Examination of the chest 
found symmetrical movement and no visible lagged 
chest breathing. First and second heart sounds is 
single, there was no noise in all ostia. Lung 
examination found no vesicular breathing sounds or 
rales and wheezing. On abdominal examination were 
found metorismus, bowel sound increase, unpalpable 
liver and spleen. Examination of the warm acral 
extremities, there was no edema or ELN. Laboratory 
results: Hb 13.6 g / dl, PCV 0.35, WBC 9,100 / ml, 
platelets (Plt) 404,000 / ml, blood sugar during 123 
mg / dl, BUN 10 mg / dl, serum creatinine SK) 1.1 
mg / dl, AST 15 U / L, ALT 13 U / L, Sodium (Na) 
123 meq / L, Potassium (K) 3.29 meq / L and 
Albumin 4.1 g / dl, cholesterol total of 193 mg / dl, 
LDL 139 mg / dl, HDL 52 mg / dl, triglyceride 68 
mg / dl, 5.9 mg / dl acids, HBsAg and non-reactive 
Anti-HCV. 
Abdominal ultrasound found a lot of gas in the 
intestine. Hepar, lien, kidney, and gallbladder were 
within normal limits. Endoscopic examination found 
a mild patch of hyperemic spots with mucosal break 
of 7 mm and Barret’s esophagus with a length of 2 
cm. The gastrointestinal and corpus portions were 
within normal limits, but hyperemia and erythema 
were present on the antrum of the pylorus. Thus, it 
was concluded to be GERD grade B and BE and 
superficial chronic gastritis were suspected. A 
biopsy was performed. 
An anatomical pathology examination report 
(PA) found a gastric gland under the esophageal 
epithelium and no dysplasia or any signs of 
malignancy with a conclusion of BE. A gastric 
biopsy found chronic superficial gastritis and 
helicobacter pylori infection did not appear. 
From anamnesis, physical examination, 
laboratory, radiologic, endoscopy and PA, the 
patient was diagnosed with GERD grade B + BE 
short segment without dysplasia + chronic 
superficial gastritis. The patient was advised to 
change their lifestyle and to undergo Rabeprazole 
therapy 2x20 mg, domperidone 3x10 mg, aspirin 
100 mg-0-0. After 2 weeks of treatment the patient's 
condition improved. The patient was advised to 
continue the therapy and undergo another endoscopy 
one year later by 2 endoscopists. 
2.2 Case 2 
A female patient, Mrs. P, 49 years old, married, 
Chinese, bachelor’s degree, a teacher, living in 
Surabaya came for treatment with major complaints 
of frequent bloating and heartburn.  
She complained of frequent bloating and 
heartburn for 8 years, frequent recurrences, which 
improved with antacid administration and rest. This 
complaint is accompanied by a burning sensation in 
the chest when consuming spicy foods, coffee or tea. 
The patient also complained of a frequent sore throat 
for the past 5 years up to twice a month and often 
had swallowing pain. There were no black feces or 
vomiting, decreased weight or fatigue. 
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There was a maxillary sinusitis 3 years ago.  
There was a history of coffee and tea consumption, 
omeprazole consumption (with a doctor’s 
prescription) twice a day for 1 month, and no history 
of smoking, alcohol consumption, high blood 
pressure or diabetes. 
A physical examination found that her general 
condition was moderate, with good awareness and 
was compos mentis. Blood pressure (BP) was 
110/70 mmHg, pulse 82 x / min, axillary 
temperature 36.7°C, respiration 20 x / min and body 
weight 60 kg TB 153 cm BMI 25.63. Examination 
of the head and neck did not find anemia, jaundice, 
cyanosis, dyspnea or enlarged lymph nodes (ELN). 
Examination of the chest did not find asymmetrical 
movement and there was no visible lagged chest 
breathing.  First and second heart sounds is single, 
no noise in all ostia. Lung examination found 
vesicular breathing sounds with no rhonchi and 
wheezing. Examination of the stomach found 
meteorismus, increased bowel sounds, and the liver 
and lien were not palpable. The examination of the 
warm acral extremities did not find edema and ELN. 
Laboratory results: Hb 12.1 g / dl, PCV 0.36, 
WBC 6510 / ml, platelets (Plt) 316,000 / ml, fasting 
blood sugar 112 mg / dl, blood sugar 2 JPP 126 mg / 
dl serum creatinine (SK), LDL 91 mg / dl, HDL 38 
mg / dl, Triglyceride 147 mg / dl, Acid vein 4.4 mg / 
dl. 
Endoscopic examination found a mild patch of 
hyperemic spots with a mucosal break of 6 mm and 
a Barret esophageal picture with a length of 5 cm. 
The gastrointestinal and corpus segments were 
within normal limits, but hyperemia and erythema 
were detected on the antrum and angulus segment. 
Thus, it was concluded as GERD grade B and BE 
and superficial chronic gastritis were suspected. A 
biopsy was performed. 
PA examination reported that under the 
esophageal epithelium there were gastric glands, but 
no dysplasia or any signs of malignancy with the 
conclusion of BE. In gastric biopsy, chronic 
superficial gastritis was found and helicobacter 
pylori infection did not appear. 
From the results of the anamnesis, physical 
examination, laboratory, endoscopy and PA, the 
patient was diagnosed as GERD grade B + BE long 
segment without dysplasia + chronic superficial 
gastritis. The patient was advised to change her 
lifestyle and undergo 2x40 mg of esomeprazole 
therapy, 3x10 mg of domperidone, aspirin 100 mg-
0-0, and ranitidine 150 mg before bed. The patient’s 
condition got better after one month of therapy. The 
patient was advised to continue the therapy and have 
another endoscopy one year later by 2 endoscopists. 
3 DISCUSSION 
For decades, BE was identified primarily in patients 
with severe GERD based on the long segmental 
findings of columnar epithelial extending more than 
3 cm above the gastroesophageal junction (Spechler, 
2002a). Clinically BE does not give symptoms; most 
people complain because of symptoms of GERD 
(Table 1). The most common symptoms of GERD 
are heartburn or pyrosis, regurgitation, and 
dysphagia. Heartburn, defined as heat in the 
retrosternal region, has a specificity of 89% and a 
positive predictive value of 81% for GERD. 
Regurgitation, defined as a reflux sensation from the 
stomach to the mouth or hypopharynx, has a 95% 
specificity and a 57% positive predictive value for 
GERD. The classic GERD symptoms rarely require 
confirmatory tests because they have a high positive 
predictive value and are sufficient to make a 
diagnosis in the majority of cases. In fact, the 
combination of heartburn and regurgitation has an 
accuracy greater than 90% for diagnosing GERD 
(Hirano, 2007).  
Extraesophageal or atypical manifestations are 
quite common in patients with GERD. As many as 
80% of patients with GERD symptoms may have at 
least one extra esophageal manifestation (Kamat, 
2008). GERD causes coughing in 40% of patients 
and GERD is found in 34-89% of patients with 
asthma (Hirano, 2007). Sinusitis may be a 
manifestation of GERD either directly injuring the 
sinus mucosa or causes vagus-mediated neuro 
inflammatory changes or both (Jecker et al., 2006).  
Table 1: Symptoms of Gastro esophagus reflux disease.  
Esophageal 
Manifestation 
An extraesophageal or atypical 
manifestation 
Oral ENT Lung
Heartburn Water-
brash
Hoarseness Asthma 
Regurgitation Burning 
sensation 
in mouth
Dysphonia Bronchitis 
Dysphagia Tongue 
sensitivity
Sore throat Pneumonia 
Halitosis Chronic 
cough 
Idiopathic 
pulmonary 
fibrosis
Source: (Kamat, 2008) 
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In patient I there were heartburn, nausea, 
vomiting, bloating and heartburn. There was a 
history of bronchitis and maxillary sinusitis for 7 
years that may be associated with GERD. In patient 
II frequent bloating and heartburn, a frequent sore 
throat and pain on swallowing were found. There 
was a history of maxillary sinusitis for 3 years 
probably related to GERD. 
Screening is recommended for patients who have 
a high risk of developing BE, i.e. male, white, aged 
> 40, duration of old GERD complaints of > 13 
years, smokers, and obesity (Sharma, 2005; Wang, 
2008). Increased BMI is a major contributor to the 
development of GERD, which in turn is a known 
risk factor for BE. Increased levels of 
proinflammatory cytokines (adipocytokines) 
including interleukin-6 and tumor necrosis factor-α, 
associated with visceral fat, have been shown to be 
expressed in patients with BE. Various biological 
mediators including leptin, insulin and insulin-like 
growth factors, which are closely related to obesity, 
are shown to stimulate cell proliferation and inhibit 
apoptosis. This may be similar to the mechanisms 
underlying the development of esophageal neoplasia 
(Kamat, 2008; Sharma, 2005).  
In patient I screening was recommended because 
he was male, having the duration of GERD of 14 
years and BMI of above normal. While in patient II 
the risk was the age of > 40 and BMI of above 
normal. The American College of Gastroenterology 
provides guidelines for the diagnosis of GERD, 
which provides empirical therapy of acid 
suppressant drugs in addition to lifestyle 
modification if the patient has symptoms of 
uncomplicated GERD. Empirical therapy is in the 
form of the provision of a proton pump inhibitor 
(PPI) such as omeprazole 20-40 mg twice daily for 1 
week. One study reported that an assessment of 40 
mg omeprazole response for 2 weeks had the same 
diagnostic efficacy value as gastric pH testing 
(Kamat, 2008). Uterine endoscopic examination 
(Upper Gastrointestinal) is a golden standard for the 
diagnosis of GERD with the presence of mucosal 
breaks in the esophagus (Table 2). It is included in 
grade B if the mucosal break is more than 5 mm but 
does not extend to the peak of the folds of two 
mucosa.  
In both patients there was a mucosal break > 5 
mm but did not extend to the peak of two mucous 
folds, thus including grade B. 
Measurement of the length of the BE segment 
requires the important participation of an 
endoscopist, because the presence of large hiatus 
hernia, ulcers / erosions, strictures etc., can reduce 
the accuracy of the assessment leading to 
overdiagnosis. The method of measurement is to 
start by identifying the gastroesophageal junction 
(GEJ) and squamocolumnar junction (SCJ) 
accurately, then measure the distance between the 
proximal SCJ and GEJ measured by endoscopy and 
recorded as the length of the BE segment (Bansal, 
2007). The length of the segment will confirm the 
high risk of progressive progression to 
adenocarcinoma. Long segments have an esophageal 
cancer risk 30 times greater than the general 
population. 
Table 2: Modification of the Los Angeles classification for 
GERD. 
Grade Description 
A Break of mucosa of < 5 mm but does not 
extend to the peak of two mucosa folds.
B Break of mucosa of > 5 mm but does not 
extend until peak folds of two mucosae.
C The mucosal break extends to the peak 
of two mucosa folds but less than 75% of 
the esophageal periphery. 
D Mucosal breaks extend to the top of two 
mucosa folds over 75% of the 
esophageal periphery 
Source (Lichtenstein et al., 2007) 
Several new imaging modalities are proposed to 
help establish the diagnosis of BE. The currently 
commercially available technique is narrow band 
imaging (NBI), a method of filtering light into two 
main colors, blue and green, which means more is 
absorbed by the blood vessels in the mucosa and 
subepithelium. This difference helps the endoscopist 
to see the mucosa better, let alone combined with 
high-resolution endoscopy. The sensitivity of NBI 
for the detection of irregular mucosal patterns is 
100% with a specificity of 98.7%. Another modality 
is autofluorescence imaging, a technology that uses 
blue lighting to detect fluorescence from cellular 
components in the esophagus. The dysplasia region 
does not have as intense autofluorescence as normal 
tissue and appears dark red. A study found that 
autofluorescence was 100% sensitive for high-class 
regions of dysplasia in 20 patients, but had a false-
positive rate of 40%. Other contrast agents such as 
violet crystal, indigo carmine, and acetic acid have 
also been proposed to improve the detection of 
mucosal patterns in Barrett's esophagus in 
combination with high-resolution endoscopes. 
Although very promising, there is not enough 
current evidence to recommend the use of clinically 
routine imaging systems (Wang, 2008).  
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In Patient I, there was a long segment of BE of 2 
cm, which included a short segment, whereas in 
patient II the segment length was 5 cm so it included 
a long segment, so theoretically had a higher risk of 
esophageal cancer. 
Dysplasia is a histological diagnosis showing 
that one or more epithelial cell clones have 
undergone a genetic alteration that makes them 
neoplastic and prone to malignancy (Spechler, 
2002a). The diagnosis of BE biopsy was classified 
with no dysplasia, low-grade dysplasia and high-
grade dysplasia. Low-grade dysplasia is most 
commonly found and is a cause of cancer. In its 
development, low grade can turn into high grade 
then sometimes turns into cancer (Poneros, 2009).   
In both patients there was no dysplasia, then 
diagnose as BE without dysplasia. 
In 2008, the American College of 
Gastroenterology recommended that the class of 
dysplasia determines the interval of surveillance 
(Table 3). 
Table 3: Grade of dysplasia, management and surveillance 
recommendations. 
No Grade of 
dysplasia 
Management Surveillance 
recommendati
on 
1 No 
dysplasia 
2 endoscopies 
with biopsy for 
confirmation 
within 1 year 
No dysplasia, 
endoscopy 
every 3 years 
2 Low-
grade 
dysplasia 
Confirmed by a 
PA expert, 
endoscopy with 
biopsy every 6 
months 
High-grade 
dysplasia -, 
endoscopy is 
performed / yr 
to no 
dysplasia 
obtained at 2 
checks
3 High-
grade 
dysplasia 
Confirmed by a 
PA expert 
Irregular 
Mucosa: 
consider 
mucosal 
resection with 
endoscopy. 
Flat mucosa: 
repeat 
endoscopy and 
biopsy every 3 
months
Confirms the 
presence of 
High-grade 
dysplasia, 3 
months of 
intensive 
surveillance, 
esophagectom
y, endoscopic 
therapy. 
Source: (Kamat, 2008) 
 
Endoscopic surveillance should be performed in 
chronic GERD patients. Ideally symptoms can be 
controlled with acid suppression therapy. This is 
important because the inflammatory process 
associated with reflux esophagitis may interfere with 
the diagnosis and BE grading and may even be 
similar to dysplasia. Endoscopic BE monitoring 
involves 4 quadrants and a biopsy taken every 1 to 2 
cm across the Barrett segment. For patients with 
intestinal metaplasia (without dysplasia), 
surveillance endoscopy should be performed twice 
in the first year to exclude dysplasia changes. 
Patients with low-grade dysplasia should undergo 
endoscopic follow up at 6 months from initial 
screening to exclude progression to high-grade 
dysplasia. Patients with high-grade dysplasia in the 
form of flat mucosa should be referred to a special 
center for further diagnostic evaluation and 
confirmation of the diagnosis by a gastrointestinal 
PA expert with endoscopies in the next 3 months 
(Kamat, 2008; Sharma, 2005).  
In both patients BE was found without dysplasia, 
so endoscopic surveillance was planned again after 1 
year by two endoscopists. 
Peitz et al. detected Helicobacter pylori (HP) in 
50% of subjects, independent of BE length (Tuncer 
et al., 2003). Some researchers have hypothesized 
that the presence of HP infections may have 
protective effects on the esophagus against 
esophageal cancer, as the gastric acid output is 
reduced (Spechler, 2002a; Laheij et al., 2002).   
In both these patients there was no helicobacter 
pylori infection. 
 Several studies have determined risk factors for 
progression to adenocarcinoma in BE patients 
(Table 4). Genetic abnormalities, developmental 
abnormalities of tumor suppressor genes, p16 and 
p53, as well as the development of tetraploid and 
aneuploid cell populations detected through flow 
cytometry and fluorescence are situ hybridization 
(FISH). Increased gastro-esophageal reflux is 
associated with increased abnormalities of 
biomarkers at all stages of molecular development, 
including p16, p53, tetraploidy and aneuploidy 
(Poneros, 2009; Souza et al., 2001; Jankowski, 
2004).  
In patient I risk factors for development into 
adenocarcinoma are a low-fat diet and fruit, 
increased BMI, make gender, heartburn and lack of 
a PPI. Patient II had risk factors of being > 40, BMI 
increase and BE long segment. Biomarkers were not 
performed on these two patients. 
The management of BE is aimed at three main 
objectives: reduction of symptoms due to GERD, 
avoiding progression to strictures and ulcers, and 
preventing progression to adenocarcinoma. Changes 
in lifestyle that must be done are BB reduction, 
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sleeping with head elevation, and avoiding smoking, 
fatty foods, coffee, chocolate, alcohol and orange 
juice. Reduction of GERD symptoms by using 
suppression of gastric acid secretion by 
administration of a H2-Antagonist Receptor (H2RA) 
or PPI. The success of antisecretic therapy for 
GERD is directly related to the degree of acid 
suppression achieved and inversely related to the 
severity of the underlying esophageal reflux. The 
presence of incompetent mechanics in the lower 
esophageal sphincter, low clearance, frequency and 
duration of reflux episodes, peristaltic wave 
amplitude in both BE types significantly lower than 
that of normal people are the basic concepts of 
GERD pathogenesis. So prokinetic drugs such as 
metoclopramide, domperidone and cisapride are 
only used as an adjuvant PPI and not given as a 
monotherapy (Fitzgerald, 2004; Schuchert, 2007). 
Table 4: Risk factors for development into 
adenocarcinoma in patients with Barret’s Esophagus.  
Clinical Factor Endoscopy 
Factor 
Histology 
factor
Diet low 
in 
vegetabl
es and 
fruit 
Working 
in 
hunchback 
position 
Large 
hiatal 
hernia 
High-grade 
dysplasia 
Increase
d BMI 
Lack of 
using a 
PPI 
BE long 
segment 
Male Symptoms 
of 
heartburn 
Mucosal 
abnormalit
ies 
Biomarker 
Old Age Use of 
drugs that 
relax the 
lower 
esophageal 
sphincter 
Nodularity Aneuploidy
Smoker Ulceration P53 loss of 
heterozygosi
ty 
Alcohol 
consume
r 
Stricturing 
Source: (Poneros, 2009) 
Patients I and II were recommended lifestyle 
changes and were given a PPI and prokinetic.  
All patients with BE should be given a PPI 
although there are no symptoms of GERD. A long-
term retrospective study of 236 patients with BE 
who received a number of different anti-reflux 
therapies showed that in 10 years, the incidence of 
cumulative dysplasia was 21% in patients receiving 
a PPI compared with 58% in patients who did not 
receive a PPI or H2RA. Another study showed that 
the risk of developing low-grade dysplasia was 5.6 
times higher in patients who started PPI therapy 2 
years or more after the diagnosis than in patients 
starting PPI therapy in the first year. In addition, 
delayed PPI therapy may increase the risk of 
progression to high-grade dysplasia or 
adenocarcinoma by 20.9%. Some researchers advise 
to add H2RA at night in addition to the use of a PPI 
twice daily to reduce acid relief (Chen et al., 2002; 
Sabel et al., 2000).  
Currently there are five types of PPI with 
comparable efficacy of omeprazole (20 mg / day), 
lansoprazole (30 mg / day), Rabeprazole (20 mg / 
day), Pantoprazole (40 mg / day) and esomeprazole 
(40 mg / day). Research using two types of PPI 
approved by the Food and Drug Administration 
(FDA), giving once or twice daily oral esomeprazole 
shows the ability to control significantly the 
intragastric acidity compared to equivalent doses of 
lansoprazole in Patients with BE. Twice daily doses 
of the drug give better control of the intragastric pH 
than once-daily dosing, and both exhibit a relative 
advantage of controlling intragastric acid with 
increasing dosage in 75% of patients with BE 
(Jankowski, 2004; Spechler et al., 2002b). Ortiz et 
al. suggested monitoring gastric pH in the titration 
process of PPI dosing (Hirano, 2007).  
Patient II was given 2 × 40 mg of esomeprazole 
PPI with 150 mg of ranitidine added in the evening. 
Patient I was given 2 x 20 mg of Rabeprazole. 
Anti-reflux surgery is attempted by creating a 
barrier to gastroesophageal reflux through an 
esophagus packing by the fundus of the stomach 
(fundoplication). This is usually performed in 
patients with low comorbidity and the presence of 
symptoms of reflux despite being treated with a PPI. 
But the long-term results are disappointing with a 5-
year failure rate of 20% (Wang, 2008). Initially, 
some researchers argued that the possibility of 
fundoplication is more effective than a PPI to 
prevent cancer deaths due to BE. Two recent studies 
provide little support for this opinion, but in one 
randomized trial of medical and surgical therapy in 
247 complicated GERD patients, adenocarcinoma of 
the esophagus occurred in four of the 165 patients in 
the medical group (2.4 percent) and one of 82 in the 
surgical group (1.2 percent) during follow up 10 to 
13 years with a statistically non-significant 
difference (Wang, 2008; Spechler, 2002a). Baulieux 
et al. reported complete or partial regression of 27% 
in patients undergoing fundoplication and 7.1% with 
PPI therapy. Ortiz et al. reported regression in 32% 
with fundoplication versus 7% with PPI on BE 
found at  segment length (Lord, 2003). Medical and 
surgical therapy is very effective for correcting or 
relieving symptoms and signs of GERD, but has not 
been shown to reduce the risk of esophageal 
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adenocarcinoma (Fitzgerald, 2004; Cooper et al., 
2006). 
In both these patients anti-reflux surgery was not 
performed.  
Chemoprevention in the prevention of 
adenocarcinoma of the esophagus represented by BE 
is considered quite rational. The best evidence of use 
of chemoprevention agents is Cyclooxygenase 
(COX) -2 inhibitors and 325-mg enteric-coated 
aspirin daily has been shown in several 
epidemiological studies and is associated with a 
significantly reduced cancer risk with a 0.57 odds 
ratio (95% CI 0.47- 0.71). This decrease in risk can 
be attributed to the effect on cyclo-oxygenase-2 
mucosal expression (COX-2) and prostaglandin E2 
production (PGE2), as both are associated with the 
development of BE into adenocarcinoma. Tsibouris 
et al. proved that BE patients with esophageal 
adenocarcinoma were rarely consumed NSAIDs 
(Poneros, 2009; Fitzgerald, 2004).  
Both patients were given aspirin 100 mg-0-0. 
Ablation therapy, ablation with thermal energy 
(thermal ablation), photodynamics, and endoscopic 
mucosal resection have now been widely used for 
BE high-grade or early-stage care. However, the 
lack of data on the usefulness of these therapies for 
BE without dysplasia is therefore not recommended. 
In the future, biomarkers may be able to provide 
better risk stratification to justify endoscopic 
ablation therapy for non-displaced BE (Poneros, 
2009; Wolfsen et al., 2002; Schuchert, 2007).   
In both patients there was no ablation, 
photodynamic or mucosal resection.  
Survival in the BE group was much better than 
the group without BE (5 years survival 61% vs. 
28%, P = 0.001). Adenocarcinoma of the esophagus 
is not a common cause of death in BE patients; the 
most common cause is bronchopneumonia and 
ischemic heart disease (Portale et al., 2005; Sabel et 
al., 2000). 
4 CONCLUSION 
This report concerns two cases of patients with Barrett's 
esophagus. In both these patients BE was found without 
dysplasia. Diagnosis was made on the basis of anamnesis, 
physical examination, laboratory, radiological, endoscopy 
and anatomical pathology. The management of BE is 
aimed at three main objectives: reduction of symptoms 
due to GERD, avoiding progression to strictures and 
ulcers, and preventing progression to adenocarcinoma. 
Both patients were given a PPI, Prokinetic and 
Chemoprevention NSAID which achieved clinical 
improvement. Both patients had no ablation, 
photodynamic or mucosal resection. BE survival is much 
better than in groups without BE (5 years survival 61% vs. 
28%, P = 0.001). 
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